MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Sells 2,099 Shares of Exact Sciences Co. (NASDAQ:EXAS)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. reduced its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 10.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,955 shares of the medical research company’s stock after selling 2,099 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Exact Sciences were worth $1,065,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of EXAS. Merit Financial Group LLC bought a new stake in shares of Exact Sciences during the 4th quarter worth $235,000. Slow Capital Inc. boosted its stake in Exact Sciences by 7.0% in the fourth quarter. Slow Capital Inc. now owns 82,001 shares of the medical research company’s stock valued at $4,608,000 after acquiring an additional 5,346 shares during the last quarter. Perigon Wealth Management LLC grew its position in shares of Exact Sciences by 3.2% during the 4th quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company’s stock valued at $474,000 after acquiring an additional 264 shares during the period. Robeco Institutional Asset Management B.V. raised its holdings in shares of Exact Sciences by 37.5% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 37,286 shares of the medical research company’s stock worth $2,095,000 after purchasing an additional 10,165 shares during the period. Finally, Forsta AP Fonden lifted its stake in Exact Sciences by 1.3% in the fourth quarter. Forsta AP Fonden now owns 39,300 shares of the medical research company’s stock valued at $2,208,000 after purchasing an additional 500 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors.

Exact Sciences Stock Up 0.8%

EXAS opened at $56.95 on Monday. The business’s fifty day simple moving average is $47.58 and its 200 day simple moving average is $51.83. Exact Sciences Co. has a 52 week low of $39.97 and a 52 week high of $72.83. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The stock has a market cap of $10.74 billion, a PE ratio of -10.22 and a beta of 0.92.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.16. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The firm had revenue of $706.79 million for the quarter, compared to the consensus estimate of $688.58 million. During the same period last year, the firm posted ($0.60) earnings per share. The business’s revenue was up 10.9% compared to the same quarter last year. As a group, research analysts expect that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EXAS has been the topic of a number of recent research reports. Guggenheim reaffirmed a “buy” rating and set a $60.00 price target on shares of Exact Sciences in a research report on Friday, April 11th. Evercore ISI upped their price objective on shares of Exact Sciences from $60.00 to $66.00 and gave the company an “outperform” rating in a report on Friday, May 2nd. Robert W. Baird lifted their target price on shares of Exact Sciences from $69.00 to $72.00 and gave the stock an “outperform” rating in a research note on Friday, May 2nd. Piper Sandler dropped their price target on shares of Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Finally, Royal Bank of Canada lifted their price objective on shares of Exact Sciences from $52.00 to $54.00 and gave the company a “sector perform” rating in a research note on Friday, May 2nd. Two research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $70.90.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.